Lipotek Pharmaceutical is based in Australia and It was founded in 2001. The offices and laboratories for this company are located on the grounds of the Australian National University campus. The company's aim is to gain ‘proof of concept’ for their Lipovaxin and Lipokel adjuvant platforms with the aim to gain strategic alliances with biotech and pharmaceutical companies. Lipotek operates primarily as a Research and Development company seeking to commercialise and create adjuvant and delivery technologies to improve vaccine formulations. In recent years this company has focused on particular diseases such as: cancer, malaria and tuberculosis.